NYLI Candriam International Equity ETFIQSI

The New York Life Candriam International Equity ETF (IQSI) is a prime example of how marketing can outshine reality. Boasting exposure to the 'best of Europe,' the fund actually delivers a concentrated basket of large-cap European stocks wrapped in a pricey fee structure. With an expense ratio of 0.59%, it’s more than double the average cost of most broad-market ETFs, making it a costly way to gain exposure to the region.

Under the hood, IQSI is far less glamorous than its name suggests. The fund tracks the Candriam International Equity Index, which is dominated by a handful of blue-chip stocks like Nestlé, Novo Nordisk, and ASML. These top three holdings alone account for nearly 15% of the portfolio, raising questions about the fund’s true diversification. As of July 2026, the fund holds just $4.5 million in assets under management, making it a small player in the ETF space.

The fund’s prospectus highlights its 'active management' approach, but the reality is more nuanced. IQSI uses a 'representative sampling' method, meaning it doesn’t hold every stock in the index. Instead, it selects a subset to mimic the index’s performance-a strategy that can lead to tracking errors. While the fund’s marketing materials may promise a curated selection of Europe’s finest, the actual product is a vanilla basket of large-cap stocks with a higher-than-average expense ratio.

For investors looking to chart IQSI’s performance, the TradingView route provides a clear picture of its market movements. The fund’s liquidity is relatively low, with average daily trading volumes under $100,000, which could pose challenges for larger investors. Meanwhile, the Candriam International Equity Index’s methodology remains opaque, leaving investors to wonder exactly what they’re paying for.

Despite the glossy marketing, IQSI’s true value proposition remains unclear. The fund’s high expense ratio, concentrated holdings, and lack of transparency around its tracking method raise questions about its long-term viability. Until the fund delivers more concrete evidence of its ability to relative strength its benchmark or justify its fees, investors may be better off looking elsewhere for European equity exposure.